YiChang HEC ChangJiang Pharmaceutical : ANNOUNCEMENT ON FINANCIAL INFORMATION FOR THE FIRST QUARTER OF 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜 昌 東 陽 光 長 江 藥 業 股 份 有 限 公 司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

ANNOUNCEMENT ON FINANCIAL INFORMATION

FOR THE FIRST QUARTER OF 2021

This announcement is made by YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the "Company", together with its subsidiaries, the "Group") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

For the three months ended 31 March 2021, due to the influence of COVID-19 pandemic, the traffic of people to medical institutions including hospitals of all levels had declined, resulting in a decrease in the sales volume of the Company's core product, Kewei. As the pandemic situation in China is under control, the amount of outpatient services is gradually increasing. Together with the development and expansion of the Group's channels including pharmacies and through internet, it is expected that the sales volume of the Group's core products will be gradually resumed in the future.

The unaudited financial information of the Group for the three months ended 31 March 2021, which were prepared in accordance with the Accounting Standards of the People's Republic of China for Business Enterprises and extracted from the management accounts of the Group is set out below:

	As at	As at
Item	31 March	31 March	Year-on-year
(Unit: RMB'000)	2021	2020	change
Operating revenue	102,360.62	2,011,360.31	-94.91%
Operating costs	37,596.83	319,860.68	-88.25%
Profit and total comprehensive income

• attributable to equity shareholders of
• the Company (without taking into account

the effect of the convertible bonds)	(132,287.13)	874,970.74	-115.12%
Profit and total comprehensive income

• attributable to equity shareholders of
• the Company (taking into account

the effect of the convertible bonds)	(207,386.87)	780,778.15	-126.56%
Total assets	8,912,179.66		11,495,261.97	-22.47%

All the aforementioned financial information are unaudited.

- 1 -

Shareholders and investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

TANG Xinfa

Chairman

Hubei, the PRC

29 April 2021

As at the date of this announcement, the board of directors of the Company consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive directors; and Mr. TANG Jianxin, Mr. ZHAO Dayao, Ms. XIANG Ling and Mr. LI Xuechen as independent non- executive directors.

- 2 -